Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (2017 - 2026)

Denali Therapeutics has reported Shares Outstanding over the past 9 years, most recently at $156.2 million for Q4 2025.

  • Quarterly Shares Outstanding rose 8.29% to $156.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $156.2 million through Dec 2025, up 8.29% year-over-year, with the annual reading at $156.2 million for FY2025, 8.29% up from the prior year.
  • Shares Outstanding was $156.2 million for Q4 2025 at Denali Therapeutics, up from $146.6 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $156.2 million in Q4 2025 and troughed at $121.1 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $137.7 million (2023), against an average of $135.5 million.
  • Year-over-year, Shares Outstanding increased 14.79% in 2021 and then increased 1.34% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $122.3 million in 2021, then rose by 11.19% to $136.0 million in 2022, then increased by 1.78% to $138.4 million in 2023, then increased by 4.22% to $144.2 million in 2024, then grew by 8.29% to $156.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Shares Outstanding are $156.2 million (Q4 2025), $146.6 million (Q3 2025), and $145.7 million (Q2 2025).